We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ebolavirus Found in Semen Months After Symptom Onset

By LabMedica International staff writers
Posted on 04 Nov 2015
Print article
Image: Colorized transmission electron micrograph (TEM) revealed some of the ultrastructural morphology displayed by an Ebolavirus virion with supplemented spermatozoa (Photo courtesy of Frederick A. Murphy/CDC, and Graphic by Mark Murrman).
Image: Colorized transmission electron micrograph (TEM) revealed some of the ultrastructural morphology displayed by an Ebolavirus virion with supplemented spermatozoa (Photo courtesy of Frederick A. Murphy/CDC, and Graphic by Mark Murrman).
The main mode of transmission is direct contact with the blood or body fluids of a person with Ebolavirus disease (EVD) or from the body of a person who died from EVD; however, Ebolavirus can persist in the body fluids of survivors during convalescence, which may result in transmission of the virus.

Previously, survivors of EVD were told to practice sexual abstinence or to use a condom for three months after recovery. These recommendations were based on virus-isolation results from semen specimens obtained from eight survivors of EVD or Marburgvirus disease in previous epidemics in which the longest period that infectious virus was found in semen after the onset of symptoms was 82 days.

A large international team of scientist led by those from the Sierra Leone Ministry of Health (Freetown, Sierra Leone) recruited a convenience sample of 100 male survivors from the Western Area District of Sierra Leone, which includes the capital of Freetown. They identified study participants who, at informational events that were held in conjunction with survivor associations, indicated interest in participation, as well as persons who were referred from Ebola treatment centers. A member of the study team administered a questionnaire to all the participants at the time of enrollment to gather information about their EVD episode, self-reported health status, sexual behavior, and sociodemographic characteristics, and the date of EVD onset was self-reported.

Semen specimens were collected and refrigerated at 5 °C to 8 °C for no longer than three days and transported to the field laboratory. The team performed quantitative reverse transcription polymerase chain reaction (RT-PCR) testing using Ebolavirus–specific gene targets (NP and VP40) and the human β2-microglobulin (B2M) gene. A specimen was considered positive if the VP40 and NP gene targets were both detected within 40 cycles of replication. The specimen was considered to be negative if neither Ebolavirus gene targets were detected nor the findings with respect to B2M status were positive. The findings were ruled to be indeterminate if either the VP40 or the NP gene target was detected but not both. Amplification of B2M served as an extraction control and RNA quality control.

A total of 46 of the 93 men (49%) had a specimen that was positive on quantitative RT-PCR. Ebolavirus RNA was detected in the semen of all 9 men from whom a specimen was obtained during the first three months after the onset of illness, in the semen of 26 of 40 men (65%) from whom a specimen was obtained at four to six months, and in the semen of 11 of 43 men (26%) from whom a specimen was obtained at seven to nine months. The longest time after the onset of a participant’s EVD symptoms that a semen specimen obtained at baseline remained positive on quantitative RT-PCR was 284 days. Indeterminate results were encountered in 10 initial specimens in the range of 152 to 273 days after the onset of symptoms.

Bruce Aylward, MD, an Assistant Director-General at the World Health Organization (Geneva, Switzerland) said, “These results come at a critically important time reminding us that while Ebola case numbers continue to plummet, Ebola survivors and their families continue to struggle with the effects of the disease. This study provides further evidence that survivors need continued, substantial support for the next 6 to12 months to meet these challenges and to ensure their partners are not exposed to potential virus.” The study was published on October 14, 2015, in the New England Journal of Medicine (NEJM).

Related Links:

Sierra Leone Ministry of Health 
World Health Organization 


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
PSA Test
Human Semen Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.